Spots Global Cancer Trial Database for sll
Every month we try and update this database with for sll cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | NCT02582879 | Chronic Lymphoc... | 18 Years - | Pharmacyclics LLC. | ||
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | NCT03588598 | Chronic Lymphoc... Small Lymphocyt... B-Cell Non-Hodg... | SHC014748M | 18 Years - 75 Years | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | NCT01253460 | Leukemia | Cyclophosphamid... Rituximab Sapacitabine | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT06291220 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab ABBV-453 | 18 Years - | AbbVie | |
| Dasatinib in Relapsed Chronic Lymphocytic Leukemia | NCT00438854 | Chronic Lymphoc... | Dasatinib | 18 Years - | Massachusetts General Hospital | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | NCT02611908 | Chronic Lymphoc... | ibrutinib obinutuzumab | 18 Years - | University of California, San Diego | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | NCT05702853 | B-cell Non Hodg... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Inj... CD19-CD34t meta... | 18 Years - | Medical University of South Carolina | |
| Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | NCT01400685 | Chronic Lymphoc... Small Lymphocyt... B Chronic Lymph... | Lenalidomide Bendamustine Rituximab | 18 Years - 80 Years | Massachusetts General Hospital | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01578707 | Relapsed or Ref... Small Lymphocyt... | ofatumumab ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | NCT02296918 | Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ... | acalabrutinib Obinutuzumab Venetoclax Rituximab | - | Acerta Pharma BV | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | NCT00535873 | Leukemia CLL Chronic Lymphoc... Small Lymphocyt... | Lenalidomide | 65 Years - | M.D. Anderson Cancer Center | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | NCT01145209 | Small Lymphocyt... CLL (Chronic Ly... | Fludarabine Pho... Ofatumumab Cyclophosphamid... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | NCT05024045 | Leukemia, Lymph... Lymphoma, B-cel... Lymphoma, Non-H... Multiple Myelom... B-cell Lymphoma Waldenstrom Mac... Lymphoma, Mantl... | LOXO-338 Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | NCT03786926 | Lymphoma | HMPL-689 | 18 Years - | Hutchmed | |
| Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) | NCT01754870 | Chronic Lymphoc... Small Lymphocyt... | Bendamustine an... | 18 Years - | University of Wisconsin, Madison | |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | NCT00546793 | NHL Lymphoma, Non-H... Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Inter... Lymphoma, Large... Lymphoma, Low-G... Lymphoma, Mixed... Lymphoma, Small... Leukemia, Lymph... Leukemia, B-Cel... Leukemia, Proly... Leukemia, Small... Lymphoma, Small... Lymphoma, Lymph... Lymphoplasmacyt... CLL SLL | veltuzumab | 18 Years - | Gilead Sciences | |
| Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | NCT01496976 | Chronic Lymphoc... Small Lymphocyt... | High Dose Methy... Ofatumumab Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL | NCT01752426 | Leukemia | Heavy Water (2H... PCI-32765 | 18 Years - | M.D. Anderson Cancer Center | |
| Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01010568 | Chronic Lymphoc... Small Lymphocyt... | Ofatumumab and ... | 18 Years - | Georgetown University | |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | NCT01168921 | CLL Leukemia | Eltrombopag | 18 Years - | M.D. Anderson Cancer Center | |
| Registry of the German CLL Study Group | NCT02863692 | CLL SLL HCL Richter´s Trans... Leukemia, Proly... Leukemia, Proly... T-LGL Leukemia NK-LGL Leukemia | 18 Years - | German CLL Study Group | ||
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | NCT02793583 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... | Ublituximab Umbralisib Bendamustine | 18 Years - | TG Therapeutics, Inc. | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease | NCT00457860 | Leukemia | Immunotoxin the... CAT-8015 immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT02046928 | Chronic Lymphoc... Small Lymphocyt... CLL SLL | A6 | 18 Years - | Ångstrom Pharmaceuticals | |
| A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers | NCT01117142 | Lymphoma, Mantl... CLL (Chronic Ly... Monoclonal B-Ce... Healthy Volunte... Small Lymphocyt... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | NCT02784834 | Chronic Lymphoc... Small Lymphocyt... | dimethyl fumara... | 18 Years - | University of California, San Diego | |
| Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | NCT04277637 | Mature B-Cell M... | BGB-11417 Zanubrutinib obinutuzumab | 18 Years - | BeiGene | |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | NCT03893682 | Chronic Lymphoc... Small Lymphocyt... Non-Hodgkin's L... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | NCT02296918 | Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ... | acalabrutinib Obinutuzumab Venetoclax Rituximab | - | Acerta Pharma BV | |
| Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | NCT04416984 | Relapsed or Ref... | ALLO-501A ALLO-647 Fludarabine Cyclophosphamid... | 18 Years - | Allogene Therapeutics | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients | NCT01520519 | Leukemia | Rituximab PCI-32765 | 18 Years - | M.D. Anderson Cancer Center | |
| Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells | NCT01362452 | Leukemia Lymphoma | T-Cell Infusion Cord Blood Infu... | 1 Year - 75 Years | M.D. Anderson Cancer Center | |
| Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | NCT02200848 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide, I... | 18 Years - | Georgetown University | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | NCT00535873 | Leukemia CLL Chronic Lymphoc... Small Lymphocyt... | Lenalidomide | 65 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab + Rituximab Consolidation in CLL | NCT00771602 | Chronic Lymphoc... Leukemia | Rituximab Alemtuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | NCT01203930 | Chronic Lymphoc... Small Lymphocyt... | Idelalisib Rituximab | 65 Years - | Gilead Sciences | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | NCT04704323 | Lymphocytic Leu... SLL | CAP-100 | 18 Years - | Catapult Therapeutics | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Vaccine Responses in Patients With B Cell Malignancies | NCT05170399 | Lymphoma | Fluzone Shingrix Flucelvax Afluria PREVNAR 13 Heplisav -B Pfizer-COVID-19... FluLaval Fluarix PNEUMOVAX 23 PREVNAR 20 AREXVY, ABRYSVO | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | NCT02005289 | Contiguous Stag... Noncontiguous S... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | MOR00208 lenalidomide Correlative Stu... | 18 Years - 80 Years | Ohio State University Comprehensive Cancer Center | |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | NCT05947851 | Leukemia, Lymph... Leukemia, Chron... Small-Cell Lymp... Lymphoma, Small... CLL SLL | Nemtabrutinib Venetoclax Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases | NCT05805605 | Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis | Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M... | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of FCN-338 in Patients With Chronic CLL/SLL | NCT04682808 | Chronic Lymphoc... Small Lymphocyt... | FCN-338 | 18 Years - | Fochon Pharmaceuticals, Ltd. | |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | NCT02005289 | Contiguous Stag... Noncontiguous S... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | MOR00208 lenalidomide Correlative Stu... | 18 Years - 80 Years | Ohio State University Comprehensive Cancer Center | |
| Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT00439231 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide | 21 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
